Navigation Links
Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL

weeks of treatment with ISIS 301012.

The most common drug-related adverse events were painless mild to moderate injection site reactions. There was one possibly drug-related serious adverse event reported for the study: a patient in the 400 mg/dL cohort experienced fever more than 12 hours after receiving the first dose and subsequently dropped out of the study. This patient was not included in the per protocol analysis. In this high dose cohort, one patient had consecutive measurements of liver transaminases (ALT) above three times the upper limit of normal (3xULN); the maximal ALT observed in the study was 211 IU/L. Importantly, no patients evidenced liver chemistries that would suggest risk of liver injury (extremely high ALT or ALT elevations together with elevations in bilirubin greater than 2xULN). Patients in this study remain in follow-up.

According to John J.P. Kastelein, M.D., Ph.D., Chairman, Department of Vascular Medicine at the Academic Medical Center in Amsterdam, The Netherlands, lead investigator in the study, "ISIS 301012 continues to show exceptional promise as a new lipid-lowering agent. This study demonstrates that as an add-on therapy in patients on statins whose LDL-C levels are not adequately controlled, ISIS 301012 effectively enables patients to achieve target levels of LDL-C. This is an important clinical effect which, together its tolerability and lack of drug interactions, make ISIS 301012 an exciting drug for potential use in combination with other lipid-lowering therapies in the patients unable to derive sufficient benefit from available agents."

Mark Wedel, M.D., J.D., Isis' Chief Medical Officer, added, "ISIS 301012 is highly active and well tolerated in combination with statins, both in the routine high cholesterol population represented in this study, as well as in homozygous familial hypercholesterolemic patients on maximal concurrent lipid-lowering therapies. ISIS 301012 continues to perform to our highest ex
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:12/15/2014)... Dec. 15, 2014 As medical device manufacturers ... Labeling) markup language standard, content teams have a greater ... to work with the standard. Starting January 2015, Data ... webinars on the benefits and the critical aspects of ... be facilitated by Howard Shatz , DCL,s SPL ...
(Date:12/15/2014)... , Dec. 15, 2014   DaVita ... one of the nation,s largest and most innovative ... its business units, DaVita Clinical Research  (DCR) and  ... to further expand its extensive clinical research and ... kidney disease (CKD) and end-stage renal disease (ESRD), ...
(Date:12/15/2014)... , December 15, 2014 Heptares ... company, is pleased to announce the grant of multiple ... relating to its GPCR-focused drug discovery platform. The ... the global patent estate covering Heptares, technologies and products ... of patents recently granted by the US Patent Office ...
Breaking Medicine Technology:Data Conversion Laboratory Helping Life Sciences Content Producers Understand the Impact and Benefits of Structured Product Labeling 2Data Conversion Laboratory Helping Life Sciences Content Producers Understand the Impact and Benefits of Structured Product Labeling 3DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 2DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 3DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 4Heptares Extends Global Patent Protection for GPCR-Focused Drug Discovery Platform With Grant of Core Patents in the United States 2
... CITY, Calif., Jan. 4, 2011 Arstasis is pleased ... to physicians, nurses, patients, and cath lab technicians across ... of physicians participating in Arstasis clinical trials and select ...  As of today, the company is making the simple-to-use, ...
... 4, 2011 Isis Pharmaceuticals, Inc. (Nasdaq: ... Recent Advances in Isis, Development PipelineWhen: , Thursday, ... 9:00 a.m. PTWhere: , www.isispharm.comHow: , Live on ... listed above. Contacts: , Kristina LemonidisDirector, Investor Relations(760) ...
Cached Medicine Technology:Nationwide Launch of Arstasis One Access Device Provides Cath Labs Across the U.S. an Alternative to Standard Arteriotomies and Vascular Closure Implants 2
(Date:12/17/2014)... Alan Mozes HealthDay Reporter ... world of infectious diseases, one worrisome phenomenon is when an ... The process -- known as zoonosis -- is not uncommon ... signs that an animal-borne disease might make inroads into the ... a development -- and the culprits in this case were ...
(Date:12/17/2014)... Alan Mozes HealthDay Reporter ... the holiday party season fast approaching, a new study reveals ... DUI arrests have fewer drunk drivers on their roads. ... more vigilantly are better able to deter inebriated revelers from ... any new laws are being passed regarding drinking and driving," ...
(Date:12/15/2014)... 15, 2014 Cancer researchers have just ... genetic causes of deadly malignant pleural mesothelioma. Surviving Mesothelioma ... their website. Click here to read it now. ... Hawaii Cancer Center, and New York’s Langone Medical Center ... mesothelioma patients in an effort to pinpoint the ...
(Date:12/15/2014)... SIMpalm, a leading mobile app development company ... its client, which allows users to keep track of ... finding the right wine. At the center of ... chemistry and wine information. All this information is assembled ... wines that are close counterparts to one another are ...
(Date:12/15/2014)... (HealthDay News) -- Expert pilots process visual information more ... make better decisions during landings, a new study shows. ... for pilots to master, and 36 percent of all ... during final approach and landing. Researchers monitored the ... experienced pilots while they were at the controls of ...
Breaking Medicine News(10 mins):Health News:Guinea Pigs Can Be Source of Serious Strep Infection 2Health News:Guinea Pigs Can Be Source of Serious Strep Infection 3Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 2Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 3Health News:New Study Reveals Genetic Mutations That May Trigger Mesothelioma, According to Surviving Mesothelioma 2Health News:Use WinMatch Connect App to Keep Track of Wines You Like 2Health News:Study Shows Why Expert Pilots Are Experts 2
... Trust for America,s Health (TFAH) ... have published a strategic climate change plan that includes a ... emergencies expected to develop from natural disasters, pollution, and infectious ... Health Problems Heat Up: Climate Change and the Public,s ...
... (Oct. 26, 2009) Rajnish Mehrotra, MD, a principal ... Medical Center (LA BioMed), will receive one of India,s ... Indian (NRI) Welfare Society of India presents annually for ... outside the country. The NRI Welfare Society will ...
... New Mexico, October 26, 2009The world,s fastest supercomputer, ... its initial "shakedown" phase doing accelerated petascale computer ... fundamental science projects. The Roadrunner system is ... assure the safety, security, and reliability of the ...
... are limiting supplies so far , MONDAY, Oct. 26 (HealthDay News) ... Americans, U.S. Health and Human Services Secretary Kathleen Sebelius said Monday ... it comes off the production line." , "We were ... soon as we got numbers we put them out to the ...
... , ... encouraging caregivers to voice their concerns about their own health as well as the people ... , ... 27, 2009 -- The ALS Association is encouraging caregivers to voice their concerns about their ...
... , , BEVERLY HILLS, Calif., Oct. ... the integration of the LifeSculpt body sculpting into the repertoire ... the world,s leading plastic surgeons, Dr. Fisher is offering LifeSculpt ... areas and enjoy fast recovery times, with little to no ...
Cached Medicine News:Health News:Only Five States Have Plans to Address the Health Impact of Climate Change, New Report Finds 2Health News:Only Five States Have Plans to Address the Health Impact of Climate Change, New Report Finds 3Health News:Only Five States Have Plans to Address the Health Impact of Climate Change, New Report Finds 4Health News:LA BioMed researcher to be honored 2Health News:Science at the petascale: Roadrunner results unveiled 2Health News:Science at the petascale: Roadrunner results unveiled 3Health News:Sebelius: There Will Be Swine Flu Vaccine for All Who Want It 2Health News:Sebelius: There Will Be Swine Flu Vaccine for All Who Want It 3Health News:The ALS Association Cares for Those Who Care the Most in New Campaign 2Health News:The ALS Association Cares for Those Who Care the Most in New Campaign 3Health News:The ALS Association Cares for Those Who Care the Most in New Campaign 4Health News:The ALS Association Cares for Those Who Care the Most in New Campaign 5Health News:The ALS Association Cares for Those Who Care the Most in New Campaign 6Health News:Garth Fisher, M.D.(R), F.A.C.S., Announces Adoption of LifeSculpt Body Sculpting Within His World-Renowned Plastic Surgery Practice 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: